Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs - Reversing the effect of elevated gastric pH with betaine HCl

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4024-4031

  Pang, Jodie ^a   Dalziel, Gena ^a   Dean, Brian ^a   Ware, Joseph A ^a   Salphati, Laurent ^a  

^a GENENTECH INC   (United States)

Author keywords

absorption; betaine HCl; dasatinib; dog; famotidine; gastric pH; GDC 0941; H2 receptor antagonist; hypochlorhydria; pentagastrin; pH dependent solubility; proton pump inhibitor

Indexed keywords

BETAINE; DASATINIB; FAMOTIDINE; PENTAGASTRIN; PICTILISIB;

ACHLORHYDRIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; STOMACH PH;

ABSORPTION; ACHLORHYDRIA; ANIMALS; ANTINEOPLASTIC AGENTS; BETAINE; DOGS; FAMOTIDINE; HYDROGEN-ION CONCENTRATION; INDAZOLES; MALE; PENTAGASTRIN; PROTON PUMP INHIBITORS; PYRIMIDINES; STOMACH; SULFONAMIDES; THIAZOLES;

EID: 84887394343     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400356m     Document Type: Article

References (27)

1. Mansfield, J. E., Jr. and Callahan, D. Nielsenhealth, the Nielsen Company Sponsored by the Consumer Healthcare Products Association. Benefits of over-the-Counter Heartburn Medication to Consumers and the Healthcare System (http://www.Chpa-Info.Org/Media/Resources/R-5333.Pdf). 2008.
2. Smelick, G. S., Heffron, T., Chu, L. K., Dean, B., West, D. A., DuVall, S. L., Lum, B. L., Budha, N. R., Holden, S. N., Benet, L. Z., Frymoyer, A., Dresser, M. J., and Ware, J. A. Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development. Mol. Pharmaceutics 2013, submitted
3. Falcon, R. W.; Kakuda, T. N. Drug Interactions between Hiv Protease Inhibitors and Acid-Reducing Agents Clin. Pharmacokinet. 2008, 47, 75-89
4. Klein, C. E.; Chiu, Y. L.; Cai, Y.; Beck, K.; King, K. R.; Causemaker, S. J.; Doan, T.; Esslinger, H. U.; Podsadecki, T. J.; Hanna, G. J. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir J. Clin. Pharmacol. 2008, 48, 553-562
5. US Food and Drug Administration. Atazanavir Sulfate (Reyataz) PrescribingInformation. (2008.
6. US Food and Drug Administration. Nelfinavir Mesylate (Viracept) Prescribing Information. (2011.
7. Lim, S. G.; Sawyerr, A. M.; Hudson, M.; Sercombe, J.; Pounder, R. E. Short Report: The Absorption of Fluconazole and Itraconazole under Conditions of Low Intragastric Acidity Aliment. Pharmacol. Ther. 1993) 7, 317-321
8. Walravens, J.; Brouwers, J.; Spriet, I.; Tack, J.; Annaert, P.; Augustijns, P. Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations Clin. Pharmacokinet. 2011, 50, 725-734
9. Budha, N. R.; Frymoyer, A.; Smelick, G. S.; Jin, J. Y.; Yago, M. R.; Dresser, M. J.; Holden, S. N.; Benet, L. Z.; Ware, J. A. Drug Absorption Interactions between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy? Clin. Pharmacol. Ther. 2012, 92, 203-213
10. US Food and Drug Administration. Dasatinib (Sprycel) DrugApproval Package. http://www.Accessdata.Fda.Gov/Drugsatfda-Docs/Nda/2006/021986-022072- Spryceltoc.Cfm. 2006.
11. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The Identification of 2-(1H-Indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer J. Med. Chem. 2008, 51, 5522-5532
12. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2 nd ed.; Marcel Dekker: New York, NY, 1982.
13. Akimoto, M.; Nagahata, N.; Furuya, A.; Fukushima, K.; Higuchi, S.; Suwa, T. Gastric pH Profiles of Beagle Dogs and Their Use as an Alternative to Human Testing Eur. J. Pharm. Biopharm. 2000, 49, 99-102
14. Lui, C. Y.; Amidon, G. L.; Berardi, R. R.; Fleisher, D.; Youngberg, C.; Dressman, J. B. Comparison of Gastrointestinal pH in Dogs and Humans: Implications on the Use of the Beagle Dog as a Model for Oral Absorption in Humans J. Pharm. Sci. 1986, 75, 271-274
15. Sagawa, K.; Li, F.; Liese, R.; Sutton, S. C. Fed and Fasted Gastric pH and Gastric Residence Time in Conscious Beagle Dogs J. Pharm. Sci. 2009, 98, 2494-2500
16. Kararli, T. T. Comparison of the Gastrointestinal Anatomy, Physiology, and Biochemistry of Humans and Commonly Used Laboratory Animals Biopharm. Drug Dispos. 1995, 16, 351-380
17. Fancher, R. M.; Zhang, H.; Sleczka, B.; Derbin, G.; Rockar, R.; Marathe, P. Development of a Canine Model to Enable the Preclinical Assessment of pH-Dependent Absorption of Test Compounds J. Pharm. Sci. 2011, 100, 2979-2988
18. Houben, G. M.; Hooi, J.; Hameeteman, W.; Stockbrugger, R. W. Twenty-Four-Hour Intragastric Acidity: 300 mg Ranitidine B.D., 20 mg Omeprazole O.M., 40 mg Omeprazole O.M. vs. Placebo Aliment. Pharmacol. Ther. 1995, 9, 649-654
19. Hurlimann, S.; Abbuhl, B.; Inauen, W. Halter, F. Comparison of Acid Inhibition by Either Oral High-Dose Ranitidine or Omeprazole Aliment. Pharmacol. Ther. 1994, 8, 193-201
20. Eley, T.; Luo, F. R.; Agrawal, S.; Sanil, A.; Manning, J.; Li, T.; Blackwood-Chirchir, A.; Bertz, R. Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects J. Clin. Pharmacol. 2009, 49, 700-709
21. Mitra, A.; Kesisoglou, F.; Beauchamp, M.; Zhu, W.; Chiti, F.; Wu, Y. Using Absorption Simulation and Gastric pH Modulated Dog Model for Formulation Development to Overcome Achlorhydria Effect Mol. Pharmaceutics 2011, 8, 2216-2223
22. Gupta, P. K.; Robinson, J. R. Gastric Emptying of Liquids in the Fasted Dog Int. J. Pharm. 1988, 43, 45-52
23. Sanaka, M.; Yamamoto, T.; Kuyama, Y. Effects of Proton Pump Inhibitors on Gastric Emptying: A Systematic Review Dig. Dis. Sci. 2010, 55, 2431-2440
24. Humphries, T. J. Famotidine: A Notable Lack of Drug Interactions Scand. J. Gastroenterol. Suppl. 1987, 134, 55-60
25. Lange, D.; Pavao, J. H.; Wu, J.; Klausner, M. Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers J. Clin. Pharmacol. 1997, 37, 535-540
26. Yago, M. R.; Frymoyer, A.; Benet, L. Z.; Smelick, G. S.; Frassetto, L.; Ding, X.; Dean, B.; Salphati, L.; Budha, N. R.; Jin, J. Y.; Dresser, M. J.; Ware, J. A. Enhanced Dasatinib Absorption in Healthy Volunteers with Pharmacologically-Induced Hypochlorhydria Using Betaine HCl. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Indianapolis, IN 2013.
27. Ware, J. A.; Dalziel, G.; Jin, J. Y.; Pellett, J. D.; Smelick, G. S.; West, D. A.; Salphati, L.; Ding, X.; Sutton, R.; Fridlyand, J.; Dresser, M. J.; Morrisson, G.; Holden, S. N. Impact of Food and Proton Pump Inhibitors on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility. Mol. Pharmaceutics 2013, submitted